글로벌 산후 우울증 시장 산업 개요 및 2031년까지의 예측 - 시장 분석 및 시장 점유율

글로벌 산후 우울증 시장 - 산업 개요

산후 우울증(PPD)은 출산 후 여성에게 발생하는 신체적, 정서적, 행동적 변화의 복잡한 혼합입니다. 기분 장애의 중요한 하위 집합으로, 슬픔과 불안에서 심한 우울증에 이르기까지 증상이 다양합니다. 글로벌 산후 우울증 시장은 항우울제 , 치료법, 천연 보충제를 포함한 다양한 제품을 포함하며, 모두 이 중요한 정신 건강 문제를 해결하는 것을 목표로 합니다. American Journal of Obstetrics and Gynecology에 따르면 산후 우울증(PPD)의 유병률은 2010년 9.4%에서 2021년 19.3%로 거의 두 배 증가하여 이 질환에 대한 인식과 진단이 증가하고 있음을 보여줍니다. 유병률의 급증은 글로벌 PPD 시장 확대에 크게 기여했는데, 효과적인 치료법에 대한 필요성이 증가함에 따라 브렉사놀론(줄레소) 및 기타 정신 건강 개입과 같은 혁신적인 치료법에 대한 수요가 증가하여 꾸준한 시장 성장으로 이어졌습니다.

Data Bridge Market Research Market Report는 최근의 새로운 개발 사항, 시장 점유율, 세분화 및 지역 분석에 따른 시장 동향, 시장 참여자의 영향, 새로운 수익 창출처 측면에서의 기회 분석, 시장 규정의 변화, 전략적 시장 성장 분석, 시장 규모, 범주 시장 성장, 응용 분야 틈새 시장 및 지배력, 제품 승인, 제품 출시, 지리적 확장, 시장의 기술 혁신에 대한 세부 정보를 제공합니다. 시장에 대한 자세한 정보를 얻으려면 Data Bridge Market Research의 전문가 분석가 팀에 문의하십시오. 저희 팀은 귀하가 사업 성장을 달성하기 위해 정보에 입각한 시장 결정을 내리는 데 도움을 드릴 것입니다.

글로벌 산후 우울증 시장 규모 및 시장 분석

The decreasing stigma around mental health is playing a crucial role in the growth of the global postpartum depression (PPD) market, as more women feel empowered to seek help for PPD without fear of judgment. Shifting societal attitudes has increased demand for effective treatments and therapies, driving the market's expansion and encouraging continued innovation in addressing this critical aspect of maternal health. As a result, Databridge Market Research dived into comprehensively analyzing the market and unveiled that the Global Postpartum Depression Market is increasing at a CAGR of 30.25%. Our detailed analysis forecasts that the market is valued at USD 8.68 billion in 2023 and is expected to grow up to USD 55.24 billion by 2031. Our meticulously created report, developed through comprehensive research and analytics, is a distinguished paper that unveils eye-opening data about the market.

Global Postpartum Depression Market Dynamics

Global Postpartum Depression Market Growth Drivers

Rising investment in healthcare infrastructure

According to the World Health Organization (WHO)'s Global Health Expenditure Report 2023, global spending on health reached a record high of USD 9.8 trillion, or 10.3% of global GDP. Substantial investment enhances the availability of resources for research, treatment, and improved access to mental health services, thereby supporting the development and dissemination of effective postpartum depression therapies. Consequently, financial boost fosters the Global Postpartum Depression Market's expansion by addressing the rising demand for postpartum depression interventions.

Reduced stigma surrounding mental health

Reduced stigma surrounding mental health issues has significantly encouraged more women to seek help for postpartum depression (PPD). According to American Psychological Association, adults aged 35 to 44 saw the most significant rise in mental health diagnoses, with 45% reporting mental illness in 2023, up from 31% in 2019. Shift towards mental health awareness supports the growth of the global postpartum depression market by increasing the demand for effective treatments, interventions ad diagnoses.

Global Postpartum Depression Market Growth Opportunities

Rising number of research and development activities

The development of new therapies, such as brexanolone (Zulresso), ketamine-based therapies, and advancements in antidepressants provide new options that target different neurotransmitter systems, offering hope to the patients who may not respond to conventional medications. Digital health mobile applications for cognitive behavioral therapy (CBT) and telehealth platforms enhance the accessibility and personalization of care, allowing for real-time, remote support, and tailored treatment plans. These innovations collectively represent significant opportunities for growth in the global postpartum depression market, as they address diverse patient needs, improve treatment outcomes, and expand the reach of effective care.

Global Postpartum Depression Market Growth Challenges

High costs associated with Postpartum Depression restricting the market growth

High costs associated with postpartum depression (PPD) treatment restrict market growth by limiting access for many patients. The significant expense of this novel therapy can lead to insurance coverage challenges and out-of-pocket costs that are prohibitive for some women. Furthermore, the cost of comprehensive mental health programs and advanced treatments can strain healthcare budgets, particularly in lower-income regions. These financial barriers restrict widespread adoption and limit the growth potential of the Global Postpartum Depression Market by preventing broader access to effective care.

Global Postpartum Depression Market Growth Restraints

Lack of standardized screening

The lack of standardized screening for postpartum depression (PPD) significantly restrains the growth of the global market by leading to missed diagnoses and lower treatment rates. In regions such as Southeast Asia and Africa, where screening practices are less consistent, a substantial number of women are not identified and treated for PPD, resulting in delayed intervention and reduced treatment uptake. This inconsistency in screening impedes market growth by limiting the number of patients accessing effective treatments and creating disparities in care, ultimately constraining the expansion of the global postpartum depression market.

Regulatory hurdles

In the Global postpartum depression (PPD) market, approval delays are a major regulatory constraint that are frequently caused by the drawn-out and intricate procedures mandated by organizations such as the FDA and EMA. For instance, it took several years for the first drug licensed particularly for PPD, brexanolone (Zulresso), to get the approval. The entire process from first proposal to approval took almost ten years, despite the breakthrough status, showing how regulatory obstacles can cause delays in the availability of novel medications. Such Delays hamper the introduction of novel medicines, which can hinder the Global Postpartum Depression Market expansion.

Global Postpartum Depression Market Scope and Trends

• CAMH-developed a natural supplement to effectively prevent postpartum blues and reduce depression symptoms, with none of the supplemented group reaching the clinical threshold for postpartum depression six months post-birth.
• The use of selective serotonin reuptake inhibitors (SSRIs), such as sertraline, to treat postpartum anxiety has increased due to their proven efficacy and safety profile, particularly for breastfeeding mothers.
• For patients 22 years of age and above receiving clinician-managed outpatient care, the FDA authorized MamaLift Plus as a prescription-only digital therapeutic. It is meant to be used for eight weeks in order to treat mild to moderate postpartum depression.

Global Postpartum Depression Market Regional Analysis- Market Trends

Key Insights

• North America leads the global postpartum depression (PPD) market, driven by advanced healthcare infrastructure, high awareness, and substantial investment in mental health. The U.S., in particular, dominates with widespread screening programs and access to innovative treatments like brexanolone (Zulresso).
• Europe is a key contributor to the growing global postpartum depression (PPD) market, driven by increased awareness, government initiatives, and robust healthcare infrastructure. Widespread screening programs support early diagnosis and treatment. Ongoing research and development in Europe further fuel market expansion with the introduction of new therapies.
• The Asia Pacific region offers significant growth potential for the global postpartum depression (PPD) market, driven by increasing awareness, improving healthcare infrastructure, and rising mental health education. As countries like China, Japan, and India recognize the importance of maternal mental health, demand for PPD treatments is expanding.
• 아프리카에서는 인식과 정신 건강 리소스가 개선됨에 따라 글로벌 산후 우울증(PPD) 시장이 성장하고 있습니다. PPD에 대한 인지도가 높아지고, 의료 인프라와 저렴한 치료 옵션이 확대되면서 이 지역의 시장 성장이 촉진되고 있습니다. 아프리카는 글로벌 PPD 시장의 핵심 기회로 부상하고 있습니다.

글로벌 산후 우울증 시장 선도 기업

• 파이저 주식회사(미국)
• GlaxoSmithKline plc (영국)
• 노바티스 AG(스위스)
• 마일런 NV(미국)
• Teva Pharmaceutical Industries Ltd. (이스라엘)
• 사노피(프랑스)
• 아스트라제네카(영국)
• 존슨앤존슨 프라이빗 리미티드(미국)
• Bayer AG(독일)
• 머크앤코(미국)
• 호프만-라 로슈 유한회사(스위스)
• 엘리 릴리 앤드 컴퍼니(미국)
• 시플라 주식회사(미국)
• Aurobindo Pharma(인도)
• 루팡(인도)
• Accord Healthcare(미국)
• Sun Pharmaceutical Industries Ltd. (인도)
• Bausch Health Companies Inc. (캐나다)
• 알보젠(미국)
• Intas Pharmaceuticals Ltd. (인도)
• 시오노기앤컴퍼니(일본)

글로벌 산후 우울증 시장 최근 동향

• 2024년 8월, 미국 식품의약국은 PTSD(외상 후 스트레스 장애)에 대한 MDMA 심리 치료를 거부했습니다.
• 2024년 7월, 비만과 산후 우울증에서 TRPC5 유전자의 역할이 발견되면서 새로운 치료법에 대한 희망이 생겼습니다.
• 2023년 7월, 미국 예방 서비스 태스크포스(USPSTF)는 임신 중 및 임신 후 PPD에 대한 보편적 검진을 권장하는 지침을 업데이트하여 조기 발견 및 개입을 개선했습니다.
• 세계보건기구(WHO)가 2024년 1월에 시작한 "산모의 정신 건강이 중요합니다" 캠페인은 산후 기간 동안 정신 건강의 중요성을 강조하여 산후 우울증에 대한 전 세계적 인식과 지원을 높이는 것을 목표로 합니다.
• 2024년에는 Perinatal Support 등의 새로운 디지털 플랫폼과 모바일 앱이 여러 개 도입되어 산후 여성을 위해 특별히 맞춤화된 가상 치료와 AI 기반 정신 건강 지원을 제공합니다.

SKU-53538